Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors

This study has been completed.

Study NCT00074321 Information provided by National Cancer Institute (NCI)

First Received: December 10, 2003 Last Updated: July 23, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Publications:

Goetz MP, Safgren S, Goldberg RM, et al.: A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7). [Abstract] J Clin Oncol 23 (Suppl 16): A-2014, 138s, 2005.